Entries by artemisthera

Artemis Therapeutics Announces Two Recent Publications Highlighting Artemisone’s Activity Against Human Cytomegalovirus And Malaria
June 19, 2018 in /by

Preclinical Data Further Supports Potential For Treatment of HCMV and Malaria SAN DIEGO, June 19, 2018 /PRNewswire/ — Artemis Therapeutics, Inc. (OTCQB: ATMS), (“Artemis” or the “Company”), a pharmaceutical company developing new therapies for the treatment of infectious diseases, including cytomegalovirus and malaria, today announced that data on its lead product candidate Artemisone have been published […]

Data Presented At The 31st International Conference For Antiviral Research Demonstrate Artemis Therapeutics’ Artemisone May Be An Effective Inhibitor Of Human CMV Replication
June 12, 2018 in /by

SAN DIEGO, June 12, 2018 /PRNewswire/ — Artemis Therapeutics, Inc. (OTCQB: ATMS), (“Artemis” or the “Company”), a pharmaceutical company developing new therapies for the treatment of infectious diseases, including cytomegalovirus and malaria, today announced that new data on its lead product candidate, Artemisone, shows it is a potent inhibitor of human cytomegalovirus (HCMV) replication in preclinical […]

New Data Demonstrate Artemis Therapeutics’ Artemisone May Be An Effective Inhibitor Of Human CMV Replication
June 7, 2018 in /by

SAN DIEGO, June 7, 2018 /PRNewswire/ — Artemis Therapeutics, Inc. (OTCQB: ATMS), (“Artemis” or the “Company”), a pharmaceutical company developing new therapies for the treatment of infectious diseases, including cytomegalovirus and malaria, today announced that new data on its lead product candidate Artemisone shows it is a potent inhibitor of human cytomegalovirus (HCMV) replication in preclinical […]

Artemis Therapeutics Announces Additional Patent Issuance For Artemisone For The Treatment Of Viral Infections
April 16, 2018 in /by

SAN DIEGO, April 16, 2018 /PRNewswire/ — Artemis Therapeutics, Inc. (OTCQB: ATMS), (“Artemis” or the “Company”), a pharmaceutical company developing new therapies for the treatment of life-threatening infectious diseases, today announced the decision by the Japanese Patent Office to allow the patent entitled “Methods and Compositions for Treating Viral Infections”. The patent covers certain compositions, including Artemisone, […]

Artemis Therapeutics Announces Issuance Of European Patent For Artemisone For The Treatment Of Viral Infections
November 28, 2017 in /by

NEW YORK, Nov. 28, 2017 /PRNewswire/ — Artemis Therapeutics, Inc. (OTCQB: ATMS), (“Artemis” or the “Company”), a pharmaceutical company developing new therapies to treat life-threatening infectious diseases, today announced the recent issuance by the European Patent Office (EPO) of European Patent No. 2839803 entitled “Methods and Compositions for Treating Viral Infections” covering the Company’s lead product candidate, […]

Artemis Therapeutics Receives Orphan Drug Designation From U.S. Food And Drug Administration For Artemisone For The Treatment Of Malaria
November 6, 2017 in /by

NEW YORK, Nov. 6, 2017 /PRNewswire/ — Artemis Therapeutics, Inc. (OTCQB: ATMS), (“Artemis” or the “Company”), a pharmaceutical company developing new therapies for the treatment of life-threatening infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for Artemisone, the Company’s lead product candidate, for the treatment of malaria. “We are […]